Prices for prescription pharmaceutical drugs have skyrocketed, disproportionately making them harder for people of color to afford, a new...
2 weeks ago

Vishal Manchanda, pharma analyst at Systematix Group and Aditya Khemka, fund manager at InCred Healthcare PMS discuss the impact of the...
6 months ago

While Dr Reddy's recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution...
8 months ago

Health systems say deals between Revlimid's owners, Celgene and Bristol-Myers Squibb, and other pharmas are anticompetitive and drive higher...
11 months ago

Celgene Corp. has thwarted rival drugmakers eager to make cheaper versions of medicines for a form of blood cancer.
76 months ago

During the congressional hearing Wednesday, Porter, a former consumer-protection attorney, tore into Alles, writing key figures in her questions...
48 months ago

Recent legislation would require drug companies to pay rebates to the federal government when annual increases in prescription drug prices...
31 months ago

For patients with certain cancers, out-of-pocket spending can exceed $15000 a year. Legislation could take aim at prices and the amounts...
35 months ago

Bristol Myers Squibb and its subsidiary Celgene allegedly conspired with generic drugmakers to create a monopoly for Revlimid, according to a new antitrust...
22 months ago

Advocates were thrilled that Medicare will negotiate the price of several insulins. But other high-profit drugs are protected by the new...
13 months ago